GSK Plc Form 6-K Summary
Business Context and Reporting Period
This Form 6-K filing by GSK Plc, dated October 16, 2025, serves as a transaction notification for the month of October 2025. The report discloses specific share acquisitions by Persons Discharging Managerial Responsibilities (PDMRs) and persons closely associated with them.
Key Financial Metrics
The filing does not provide consolidated financial metrics such as revenue, profit, cash flow, margins, debt, or liquidity. It focuses exclusively on individual insider trading activity.
Material Changes and Transaction Details
Three separate transactions were reported on October 14, 2025, on the New York Stock Exchange (XNYS). All transactions involved the acquisition of American Depositary Shares (ADSs) (ISIN: US37733W2044) following the re-investment of dividends paid to shareholders on October 9, 2025. The transactions were executed at a uniform price of $43.9461 per ADS.
- Dr. Hal Barron (Non-Executive Director): Acquired 3,186.736 ADSs.
- James Ford (SVP and Group General Counsel, Legal and Compliance): Acquired 321.543 ADSs.
- Shobie Ramakrishnan (Chief Digital and Technology Officer): Acquired 387.334 ADSs.
Guidance, Outlook, and Risks
The filing text does not provide management commentary, financial guidance, outlook, risk factors, contingencies, or unusual items. The document is strictly a regulatory disclosure of insider share purchases.
Key Facts for Investor Verification
- Verify the dividend payment date of October 9, 2025, to confirm the source of funds for these reinvestments.
- Confirm the total number of ADSs held by the named executives post-transaction to assess their overall equity exposure.
- Note that the transaction price of $43.9461 reflects the market value on October 14, 2025.
- Recognize that this filing contains no operational or financial performance data for the company.